Lexaria Bioscience Corp. announced on February 24, 2025, that it has received lead clinical site human research ethics committee (HREC) approval for the fifth study arm of its Phase 1b, 12-week chronic study GLP-1-H24-4 in Australia.
This newly approved arm will evaluate DehydraTECH-tirzepatide capsules, complementing the initial four arms that include DehydraTECH-CBD, DehydraTECH-semaglutide, a combination of both, and Rybelsus® tablets as a control. This approval allows for the study of two dominant GLP-1 drugs, semaglutide and tirzepatide, within a single trial.
The ability to study both semaglutide and tirzepatide, which together comprise over 90% of the global GLP-1 market, is a significant achievement for Lexaria. This expansion enhances the potential to demonstrate the broad applicability and benefits of its DehydraTECH oral delivery technology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.